Reporter ribozymes that allow monitoring of protein–nucleic acid and protein–protein interactions facilitate rapid identification of inhibitors for use in drug discovery.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ellington, A.D. & Szostak, J.W. Nature 346, 818–822 (1990).
Tuerk, C. & Gold, L. Science 249, 505–510 (1990).
Eaton, B.E., Gold, L. & Zichi, D.A. Chem. Biol. 2, 633–638 (1995).
Ellington, A.D. & Conrad, R. Biotechnol. Annu. Rev. 1, 185–214 (1995)
Hartig J.S. et al. Nat. Biotechnol. 20, 717–722 (2002).
Seetharaman, S., Zivarts, M., Sudarsan, N. & Breaker, R.R. Nat. Biotechnol. 19, 336–341 (2001).
Robertson, M.P. & Ellington, A.D. Nucleic Acids Res. 28, 1751–1759 (2000).
Hesselberth, J., Robertson, M.P., Jhaveri, S. & Ellington, A.D. J. Biotechnol. 74, 15–25 (2000).
Green, L.S., Bell, C. & Janjic, N. Aptamers as reagents for high throughput screening. BioTechniques 30, 1094–1110 (2001).
Fredriksson, S. et al. Nat. Biotechnol. 20, 473–477 (2002).
Petach, H. & Gold, L. Curr. Opin. Biotechnol., in press (2002).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gold, L. RNA as the catalyst for drug screening. Nat Biotechnol 20, 671–672 (2002). https://doi.org/10.1038/nbt0702-671
Issue Date:
DOI: https://doi.org/10.1038/nbt0702-671